SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to offer pre-IPO exposure to SpaceX, with many community members labeling it a scam and warning against potential pump-and-dump schemes. While participants look for ways to gain exposure to the rumored SpaceX IPO through related stocks and space-sector ETFs, experts emphasize that official equity is not currently available to the public.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing intense community engagement as investors debate its potential for a major breakout, with the conversation dominated by meme-centric hype, speculative price predictions, and comparisons to other viral meme tokens. The discussion remains polarized between bullish sentiment fueled by historical price action and skepticism regarding the long-term utility of the project.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending as the community debates Bitcoin's long-term trajectory and institutional adoption, with sentiment split between long-term bullish holders betting on cyclical gains and short-term traders warning of potential volatility as BTC faces resistance levels. Investors are actively discussing the impact of broader economic indicators, regulatory shifts, and leverage trends on the asset's momentum.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is capturing intense retail attention as investors bet on its potential to challenge the domestic supply chain for rare earth magnets. The community is focused on the stock's low-float, volatile trading patterns, with active discussions debating whether its tech-integrated mining approach is a legitimate long-term play or a short-term pump and dump.

Investment Managers Series Trust II - Tradr 2X Long AAOI Daily ETF

The Tradr 2X Long AAOI Daily ETF

AAOX is generating significant community conversation as a leveraged vehicle for traders looking to amplify their exposure to the volatile price action in Applied Optoelectronics. Investors are actively debating the merits of this high-risk tool, focusing on its use for short-term momentum plays and potential short squeezes within the broader optical networking and AI-related tech sector.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is trending as investors debate the potential of its DePin infrastructure and long-term utility against persistent frustration over its history of pump-and-dump price action. Community sentiment remains deeply polarized, with many users expressing skepticism over past broken promises and project leadership while others aggressively accumulate, citing bullish signals and upcoming ecosystem developments.

Sprinklr, Inc. engages in the provision of enterprise cloud software products. It enables organizations to do marketing, advertising, research, care, sales, and engagement across modern channels including social, messaging, chat, and text through its unified customer experience management software platform. The company was founded by Ragy Thomas on September 24, 2009 and is headquartered in New York, NY.

Sprinklr Inc - Ordinary Shares Class A

Sprinklr Inc

Sprinklr is trending as investors weigh significant insider selling and legal concerns against bullish sentiment driven by institutional accumulation and the company's AI-native platform. The community is actively debating whether the stock's recent price pressure creates a long-term value opportunity or reflects ongoing governance and growth challenges.

Canadian Natural Resources Ltd. is an oil and natural gas production company, which engages in the exploration, development, marketing, and production of crude oil and natural gas. It operates through the following segments: Oil Sands Mining & Upgrading, Midstream & Refining, and Exploration & Production. The Oil Sands Mining & Upgrading segment produces synthetic crude oil through bitumen mining and upgrading operations. The Midstream & Refining segment focuses on maintaining pipeline operations and investment. The Exploration & Production segment consists of operations in North America, largely in Western Canada, the United Kingdom portion of the North Sea, and Côte d’Ivoire and South Africa in Africa. The company was founded on November 7, 1973 and is headquartered in Calgary, Canada.

Canadian Natural Resources Ltd.

Canadian Natural Resources is trending as investors highlight its resilient oil sands production, consistent dividend growth streak, and strong cash flow generation despite broader market volatility. The community remains focused on the company's status as a top-tier energy producer, emphasizing its long-term value and operational efficiency in an evolving energy landscape.

Vanguard World Fund - Vanguard Energy ETF

Vanguard Energy ETF

Vanguard Energy ETF (VDE) is trending as investors react to high energy prices, geopolitical tensions in the Middle East, and ongoing concerns regarding global supply chain disruptions. Community members are actively debating the long-term growth potential of energy assets amidst persistent inflationary pressures and shifting supply-demand dynamics.

APA Corp. explores for oil and natural gas through its subsidiaries. It produces oil and gas with operations in the United States, Egypt and the United Kingdom, and exploration activities offshore in Suriname. The company was founded in 1954 and is headquartered in Houston, TX.

APA Corporation

APA Corporation is trending as investors weigh recent workforce reductions alongside ongoing speculation regarding potential M&A activity and the company's long-term exploration projects in Suriname. Community discussions are heavily focused on the stock's perceived undervaluation relative to its assets and the broader impact of geopolitical volatility on energy sector sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

<ul class="summary-bullets"><li>CRISPR Therapeutics said the debt securities will rank as senior unsecured obligations.</li><li>Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.</li><li>In January, the company said it had around $2 billion in cash, cash equivalents, and marketable securities.</li></ul>CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts.&nbsp;The company said it intends to issue $350 million in convertible senior notes, scheduled to mature in 2031, subject to prevailing market conditions and investor demand.<h2 class="st-heading-2">Structure Of The Convertible Notes</h2>According to the company, the debt securities will rank as senior unsecured obligations.&nbsp;Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.&nbsp;Unless the notes are converted into shares, repurchased, or redeemed earlier, they will come due on Mar. 1, 2031. If investors choose to convert the notes, CRISPR will settle the conversion by issuing common shares with a nominal value of CHF 0.03 ($0.039) each.CRISPR Therapeutics said it expects to allocate the net proceeds from the sale for broad corporate needs.&nbsp;<a href="https://stocktwits.com/symbol/CRSP">CRISPR Therapeutics stock</a> traded over 6% lower in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">2026 Goals</h2>CRISPR Therapeutics is developing a wide range of programs in blood disorders, cancer, regenerative medicine, heart and autoimmune diseases, and other rare conditions. CASGEVY is the first CRISPR-based therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia.In January, it&nbsp;outlined its strategic priorities for 2026, highlighting multiple expected milestones across its gene-editing and siRNA portfolios. It also emphasized a strong financial position, with around $2 billion in cash, cash equivalents, and marketable securities to support ongoing research and commercial activities.CRSP stock has gained over 23% in the last 12 months.&nbsp;Exchange Rate: 1CHF=1.29USDAlso See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-surged-today-what-is-fueling-the-rally/cZdovHXRI7O">CAPR Stock Surged 17% Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crispr Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Is CRSP Stock Falling Pre-Market Today?

CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts. 

Why Is CRSP (CRISPR Therapeutics) Stock Falling Pre-Market Today?

Equity

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.


<ul class="summary-bullets"><li>The German drugmaker will transfer select intellectual property to the new entity while retaining a minority stake.</li><li>The new entity will operate independently with its own financial structure, research agenda, and operational framework.</li><li>BioNTech will continue concentrating on its expanding late-stage development portfolio.</li></ul>BioNTech SE (BNTX) on Tuesday revealed plans to launch a separate biotechnology venture dedicated to advancing next-generation messenger RNA technologies, with the initiative to be led by its co-founders Ugur Sahin and Prof. Özlem Türeci, who are set to leave the company to head the new venture.&nbsp;&nbsp;The new entity will operate independently with its own financial structure, research agenda, and operational framework while collaborating with BioNTech in specific areas of development.Following the announcement, BioNTech stock tumbled nearly 17% in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h3>Founders Exit To Lead New mRNA Venture</h3>The Germany-based company intends to transfer certain intellectual property and technology assets tied to mRNA research to the new organization while retaining a minority ownership stake and potential milestone or royalty payments.The forthcoming company will concentrate exclusively on developing emerging mRNA platform technologies with potential medical applications.<h3>BioNTech Keeps Focus On Oncology Pipeline</h3>While the new venture focuses on experimental mRNA innovation, BioNTech will continue concentrating on its expanding late-stage development portfolio. The company expects around 15 Phase 3 clinical trials in oncology to be underway by the end of 2026.&nbsp;“We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organization to drive meaningful impact for patients”.-Helmut Jeggle, Chairman, BioNTech Supervisory Board<h2 class="st-heading-2">Q4 Earnings Pressure&nbsp;</h2>BioNTech reported a 23% year-on-year (YoY) decline in fourth-quarter earnings to €907.4 million ($1.05 billion). Loss per share also widened to €1.25 from a loss per share of €0.33 last year.&nbsp;BNTX stock has declined by 3% in the last 12 months.&nbsp;Conversion Rate: €1=$1.16Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/att-250-billion-fiber-5g-network-investment-plan/cZdoY58RIew">AT&amp;T Is Spending $250B On Connectivity In The US – Here’s Where The Money Is Going</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioNTech mRNA-based vaccine manufacturing site in Rwanda | Source: BioNTech

Why Did BNTX Stock Tumble 17% Pre-Market Today? 

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  

<ul class="summary-bullets"><li>Moderna has submitted a revised approach to streamline approval based on age-specific indications.</li><li>The company proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults 65 and older.</li><li>Last week, the FDA refused to review Moderna’s application for the flu vaccine.</li></ul>Moderna, Inc. (MRNA) said on Wednesday that it is moving forward with regulatory review for its investigational seasonal flu vaccine, mRNA-1010, after responding to a prior Refusal-to-File letter from the U.S. Food and Drug Administration (FDA).&nbsp;The company has submitted a revised approach to streamline approvals based on age-specific indications.<h2 class="st-heading-2">Targeted Approval Strategy</h2>Moderna proposed a dual-pathway regulatory strategy, seeking full FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older, along with a post-marketing study to further evaluate safety and efficacy in older populations.The FDA has now accepted the biologics license application (BLA) for review, setting a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 5, 2026.<blockquote>"Pending FDA approval, we look forward to making our flu vaccine available later this year so that America's seniors have access to a new option to protect themselves against flu."-Stéphane Bancel, CEO, Moderna</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> traded over 5% higher on Wednesday morning. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_18_091941_png_316eca4dee.webp" alt="MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>MRNA’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Feb. 18, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global Regulatory Progress</h2>mRNA-1010 has entered regulatory review not only in the U.S. but also in Europe, Canada, and Australia, with additional filings planned for later in 2026. Moderna anticipates the first potential approvals for the vaccine to occur within the year.If approved, mRNA-1010 would be available for U.S. adults aged 50 and above, including those 65 and older, for the 2026/2027 influenza season.&nbsp;Last week, the FDA refused to review Moderna’s application for the flu vaccine and cited the lack of an "adequate and well-controlled" study with a comparator arm that "does not reflect the best-available standard of care."&nbsp;MRNA stock has gained over 28% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/walmart-earnings-can-wmt-stock-sustain-momentum-under-new-ceo/cZR0ZxRR4Hs">Walmart Earnings Ahead: Can WMT Stock Sustain Momentum Under New CEO?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

GNOM
Global X Funds - Global X Genomics & Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest GNOM News

GNOMGlobal X Funds - Global X Genomics & Biotechnology ETF